IPX · IperionX Limited · Stock research

Current Thesis

The leg that carried IperionX to $60.11 — domestic titanium metal re-rated on critical-minerals sovereignty flow — is not the leg on offer today. The 2026-07-08 placement of 2,275,000 ADS at $21.98, roughly 22% under the ~$28 pre-deal level, showed where the marginal institutional bid actually sat, and price has not travelled far from it since: a close of $22.50 on 2026-08-21, six weeks inside a rough $22–24 range, 62.6% below the 52-week high and 40.2% lower over three months, with RSI(14) at 53.6. What an investor buys here is a corporate restructuring idea plus an unproven operational ramp. The corporate part is the 2026-08-03 proposal to redomicile under a Texas-incorporated ultimate parent whose common stock would list directly on Nasdaq, retiring the ADS line — announced with no shareholder-meeting date, no court date and no scheme booklet, and still undated as of 2026-08-23. The tape has since gone silent — StockTitan's news index shows no company release between the 2026-08-05 investor webinar and 2026-08-23. The FY26 Appendix 4E, due under ASX Listing Rule 4.3A within two months of the 30 June balance date, is the first event that can put a full-year number against any of it.

Bullish and bearish views on IperionX Limited

The model's bull view on IperionX Limited (IPX), in brief: A structural discount gets a named remedy, 2026-08-03. The bear view: Still no revenue line. The 2026-07-30 June quarterly describes prototype production, product development, qualification testing and low-rate initial production across defense, aerospace, automotive, consumer electronics and industrial customers, and discloses no customer revenue… Both cases follow in full.

Bull Case

• A structural discount gets a named remedy, 2026-08-03. A newly incorporated Texas parent would become the group's ultimate parent, with Nasdaq-listed common stock replacing the ADS structure, subject to shareholder, court, regulatory and exchange approvals. StockTitan recorded a +3.95% close that session after a +10.7% intraday peak — the largest single-headline response since the July raise.
• Near-term funding pressure is answered, 2026-07-30 quarterly. Cash US$35.2M at 2026-06-30; pro-forma ~US$84M including the US$50M ADS offering and a US$2.4M DPA reimbursement received after quarter-end.
• Government money is contracted, not aspirational. The June quarterly disclosed US$37.1M of remaining obligated reimbursable U.S. Government funding within the DPA Title III framework against the US$12.7M award, with US$2.4M reimbursed post-quarter.
• Titan DFS economics, 2026-06-04: US$813M after-tax NPV8, 39.4% IRR, US$381.3M development capex, 3.6-year payback, with a Dy/Tb/Y heavy-rare-earth concentrate in the same flowsheet.
• Board matched to the corporate plan, effective 2026-08-03: Michael J. Loparco appointed independent non-executive director, an advanced-manufacturing and global supply-chain executive.
• Published sell-side has not marked down. Aggregator consensus in August 2026 shows 5 Buy / 0 Sell across six analysts, a median target near $53 inside a $40–$71 range, against the $23.57 close of 2026-08-14. No covering broker has been observed cutting below the $40 bottom of that range.

Bear Case

• Still no revenue line. The 2026-07-30 June quarterly describes prototype production, product development, qualification testing and low-rate initial production across defense, aerospace, automotive, consumer electronics and industrial customers, and discloses no customer revenue figure for the quarter.
• The ramp hit a physical constraint. Virginia HAMR operations ran 24/7 but output was temporarily reduced by furnace downtime during the June quarter, against the ~200 tpa end-CY2026 target.
• Cash landed under the prior guide. US$35.2M at 2026-06-30 versus the US$36–40M range previously indicated.
• The 2026-08-21 close of $22.50 sits between that print and the $21.66 52-week low — the raise has not been left behind.
• Titan is unfunded. US$381.3M of development capex sits against ~US$84M pro-forma cash, so project financing is a separate levered-or-dilutive event well ahead of 1,400 tpa titanium metal in mid-2027+.
• The restructuring is an intention, not a schedule. Twenty days after the 2026-08-03 release there is no scheme booklet, no notice of meeting and no published Nasdaq listing date.
• Securities investigations remain open. Law-firm investigation notices over the right-of-use restatement (Glancy Prongay, Holzer & Holzer, Frank R. Cruz) have been outstanding since March 2026 with no filed complaint and no resolution disclosed.
• Flow has thinned. No company release from 2026-08-05 to 2026-08-23; the last dated headline response was three weeks ago.

Setup & Price Structure

Reference close 2026-08-21: $22.50. The 52-week high is $60.11, leaving the shares 62.6% below it, with a three-month price change of -40.2% and RSI(14) at 53.6 — mid-range, neither washed out nor extended. Kalkine reported the ASX line IPX.AX at A$3.06, down 6.55%, on 2026-08-19, so weakness is being set overnight in Australia and imported into US sessions rather than originated on Nasdaq.

The structure is a floor test, not a base. Two levels sit immediately underneath: the $21.98 July placement price, at which US$50M of new stock was absorbed, and the $21.66 52-week low. Price has spent six weeks between roughly $22 and $24 without approaching the low-$30s shelf that the stock lost on the way down. A range that holds under repeated tests eventually becomes a base; one that has produced no upside expansion on its only fresh headline (2026-08-03) has not yet done so.

The narrative is dead for the leg that ran to $60.11. What dates it — a 40.2% three-month decline, a July equity raise cleared only at a ~22% discount, a 52-week low printed at $21.66 in July, and no reclaim of the low-$30s in the seven weeks since. The redomiciliation is an attempt to start a second leg; a +3.95% close on 2026-08-03 that faded from a +10.7% intraday high, followed by 18 days of silence, is not yet evidence that one has started.

Crowding and positioning observables, stated as observed: the shares trade far below every reference from the prior advance rather than extended above a rising average, so there is no distance-above-trend crowding signal here. The published analyst cluster is the one crowded object — 5 Buy / 0 Sell, median near $53 against a $22.50 close — coverage that has not been revised down and therefore carries downgrade risk rather than support. Supply was issued into weakness, not strength: the July placement was priced below market, and roughly 7% dilution was added at the lows. There is no imminent US-style earnings call; the reporting cadence is the ASX Appendix 4E and quarterly 4C. Retail-sentiment clustering shows up mainly as law-firm investigation notices dating to March 2026, not as fresh promotional coverage. Insider transaction data for the period is not in hand and is not asserted.

Catalyst Calendar (next 30 days)

• ~2026-08-31 (est.) — FY26 preliminary final report (ASX Appendix 4E), due within two months of the 30 June year-end under ASX Listing Rule 4.3A. First full-year statements after the Titan DFS and the July raise; resolves whether any FY26 revenue is recognised and what full-year operating outflow looks like against ~US$84M pro-forma cash.
• ~2026-09-30 (est.) — FY26 annual report under the ASX three-month lodgement rule (just outside the 30-day window). The natural venue for a redomiciliation timetable, restatement-related disclosure and audited commentary on the right-of-use correction behind the March 2026 investigations.
• ~2026-10-27 (est.) — September-quarter Appendix 4C cash report (March quarter landed 2026-04-27, June quarter 2026-07-30). First quarterly that can show recovery from furnace downtime toward the ~200 tpa end-CY2026 run-rate, and any first customer receipts.

Elapsed catalysts

• Not yet dated as of 2026-08-23 — scheme booklet / notice of meeting setting a shareholder-vote date for the Texas redomiciliation. Until one is lodged the corporate leg has no gradeable date attached to it. (passed 3d ago)

What Would Change Our Mind

The structure that has to hold is the July placement shelf. US$50M of stock was cleared at $21.98 and the 52-week low sits at $21.66; losing both on a weekly close below $21.66 would say the buyers who took the discounted paper are underwater and no sovereignty bid replaced them, at which point the six-week $22–24 range reads as distribution rather than accumulation. Two secondary conditions carry the same weight: a second discounted equity raise, convertible or at-the-market program priced at or under the July level, which would confirm that ~US$84M pro-forma cash cannot carry the company to first revenue; and the FY26 Appendix 4E around 2026-08-31 arriving with no customer revenue recognised for the full year and no restated timetable for the ~200 tpa run-rate.

The reverse case is equally specific. A shareholder-meeting date and scheme booklet for the Texas parent, a first disclosed customer revenue figure in the 4E or the September 4C, or a sustained reclaim of the low-$30s on expanding volume would each mark the second leg actually beginning. Absent those, the name is a pre-revenue developer whose last funding event was priced at a discount, and the case for a fresh commitment at $22.50 is weak.

Correlation Notes

• Dual listing drives the open. IPX.AX on the ASX sets price overnight; the Nasdaq ADS represents 10 ordinary shares, so US sessions inherit Australian moves — the reported -6.55% ASX session on 2026-08-19 is the mechanism, not a US-originated sell.
• Policy beta, not commodity beta. The revenue case rests on DPA Title III reimbursements and US defense/aerospace qualification schedules, so the name tracks US critical-minerals policy headlines and defense appropriations more closely than any spot titanium quote.
• Critical-minerals complex. Moves with the US rare-earth and strategic-metals cohort on sovereignty headlines; the Titan DFS Dy/Tb/Y concentrate adds direct rare-earth sensitivity alongside titanium.
• AUD/USD is an embedded cross. Costs and the primary listing are Australian while the growth capex and customers are US-dollar, so the ADS price carries an FX leg independent of company news.
• Small-cap pre-revenue funding conditions. With US$381.3M of Titan capex unfunded, the name is levered to the equity-issuance window for development-stage industrials; a shut window matters more here than the titanium price.